Table 2.
Thirty miRNAs change over time in PCOS women. Shown are the mean fold change ± standard deviation as well as the number of women included. Changes in expression levels were evaluated with a paired student t-test. p values were corrected for multiple testing using Bonferroni corrections. MiRNAs are human miRNAs (hsa-miR) unless otherwise specified. Some assays were designed for murine miRNAs, but in these cases, the miRNA was completely homologous. PCOS (FF): Levels in follicular fluid associated with PCOS, PCOS (circulating): Levels in circulation associated with PCOS. NAFLD: Non-alcoholic fatty liver disease.
| miRNA | Reported Association | Difference in dCt ± SD | Direction | n | p | padj |
|---|---|---|---|---|---|---|
| miR-451a | PCOS (circulating) | 6.3 ± 3.2 | Decreased | 34 | 5.7 × 10−13 | 5.5 × 10−11 |
| miR-24-3p | PCOS (FF) | 5.8 ± 5.2 | Decreased | 42 | 8.4 × 10−9 | 8.1 × 10−7 |
| miR-16-5p | PCOS | 5.3 ± 3.1 | Decreased | 39 | 4.8 × 10−13 | 4.6 × 10−11 |
| miR-21-5p | PCOS (circulating) | 4.6 ± 3 | Decreased | 27 | 2.2 × 10−8 | 2.1 × 10−6 |
| miR-142-3p | Dysregulated in PCOS granulosa cells | 4.5 ± 3.3 | Decreased | 24 | 8.4 × 10−7 | 8.1 × 10−5 |
| miR-223-3p | PCOS (circulating | 4.5 ± 3.2 | Decreased | 43 | 1.4 × 10−11 | 1.3 × 10−9 |
| miR-720 | PCOS (FF) | 4.1 ± 3.2 | Decreased | 44 | 1.1 × 10−10 | 1.1 × 10−8 |
| miR-19b-3p | PCOS (circulating) | 4 ± 3 | Decreased | 38 | 7.3 × 10−10 | 7.0 × 10−8 |
| miR-151-3p | PCOS (FF) | 3.8 ± 2 | Decreased | 36 | 2.2 × 10−13 | 2.1 × 10−11 |
| miR-342-3p | Circulating levels associated with insulin resistance | 3.7 ± 2.7 | Decreased | 35 | 2.3 × 10−9 | 2.2 × 10−7 |
| miR-146a-5p | PCOS (circulating) | 3.6 ± 2.5 | Decreased | 39 | 7.4 × 10−11 | 7.1 × 10−9 |
| miR-126-3p | PCOS (circulating) | 3.4 ± 2.6 | Decreased | 37 | 3.6 × 10−9 | 3.4 × 10−7 |
| miR-93-5p | PCOS (circulating) | 3.2 ± 2.5 | Decreased | 35 | 9.9 × 10−9 | 9.5 × 10−7 |
| miR-145-5p | PCOS (circulating) | 3.2 ± 2.1 | Decreased | 32 | 1.5 × 10−9 | 1.5 × 10−7 |
| miR-1305 | Circulating biomarkers of ovarian cancer | 3.1 ± 5.9 | Decreased | 24 | 1.6 × 10−2 | 1.0 |
| miR-320a-3p | PCOS (FF) | 3.1 ± 1.8 | Decreased | 42 | 3.2 × 10−14 | 3.1 × 10−12 |
| miR-151-5p | PCOS (FF) | 2.7 ± 4.2 | Decreased | 29 | 1.8 × 10−3 | 0.17 |
| miR-17-5p | Circulating biomarkers of metabolic syndrome | 2.7 ± 2.6 | Decreased | 41 | 9.8 × 10−8 | 9.4 × 10−6 |
| miR-423-5p | Dysregulated in PCOS granulosa cells | 2.5 ± 1.8 | Decreased | 33 | 4.0 × 10−9 | 3.8 × 10−7 |
| miR-139-5p | PCOS (circulating) | 2.5 ± 2.0 | Decreased | 30 | 2.4 × 10−7 | 2.3 × 10−5 |
| miR-28-3p | Granulosa cell proliferation | 2.3 ± 1.8 | Decreased | 25 | 7.9 × 10−7 | 7.6 × 10−5 |
| miR-30b-5p | Associated with NAFLD | 2.2 ± 2.4 | Decreased | 33 | 6.8 × 10−6 | 6.6 × 10−4 |
| miR-30c-5p | PCOS (circulating) | 2.2 ± 2.3 | Decreased | 37 | 1.2 × 10−6 | 1.2 × 10−4 |
| miR-20a-5p | PCOS (circulating) | 1.9 ± 2.9 | Decreased | 33 | 5.4 × 10−4 | 0.052 |
| miR-222-3p | PCOS (circulating) | 1.8 ± 2.5 | Decreased | 35 | 2.1 × 10−4 | 0.020 |
| miR-221-3p | Associated with inflammation | 1.7 ± 2.5 | Decreased | 26 | 1.4 × 10−3 | 0.130 |
| miR-1233-3p | Circulating biomarkers of ovarian cancer | 5.5 ± 7.1 | Increased | 28 | 3.2 × 10−4 | 0.031 |
| miR-518f-3p | PCOS (FF) | 6.6 ± 6.3 | Increased | 34 | 7.9 × 10−7 | 7.6 × 10−5 |
| miR-520c-3p | PCOS (FF) | 8.4 ± 8.1 | Increased | 30 | 3.7 × 10−6 | 3.6 × 10−4 |
| miR-618 | Not previously published | 10.3 ± 7.5 | Increased | 29 | 5.1 × 10−8 | 4.9 × 10−6 |